NCT Number: NCT00742833
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Japan, Hokkaido Region
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with a symptom of overactive bladder for more than 6 months.
- Patients who meet the following condition during the 3-day bladder diary period.
- the mean number of micturitions per 24 hours is ≥8 times
- the mean number of urgency episodes per 24 hours is ≥1 time
Exclusion criteria
- Patients who are diagnosed as stress urinary incontinence are predominant.
- Patients with urinary calculus, interstitial cystitis, or clinically significant urinary tract infection.
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Change from baseline in mean number of micturitions per 24 hours
Time frame: 12 weeks
Secondary outcomes
-
Change from baseline in mean number of urgency episodes per 24 hours
Time frame: 12 weeks
-
Change from baseline in mean number of incontinence episodes per 24 hours
Time frame: 12 weeks
Sponsors and collaborators
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Registry information
Official study title
A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder
Important dates
- First posted
- Aug 28, 2008
- Registry last updated
- Sep 4, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Wuhan, Hubei, China
View Trial DetailsAquarius Pilot Study to Evaluate the New Axonics Trial System
NCT07335484
Digestive System Diseases, Fecal Incontinence
North Adelaide, South Australia, Australia
View Trial DetailsPMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Chicago, Illinois, United States
View Trial DetailsLow-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
NCT07473310
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Al Mansurah, Dakahlia Governorate, Egypt
View Trial Details